A Common Technical Document is a standardized way to organize information about a medicine or medical device

A Common Technical Document, or CTD, is a single organized file that contains all the scientific, manufacturing, and safety information a company needs to submit when asking a government agency to approve a new medicine or medical device. Instead of each country requiring its own separate format and organization, the CTD lets companies submit the same document to regulators in the United States, Europe, Japan, and other countries that accept it.

The CTD was created so pharmaceutical and device companies would not have to rewrite and reorganize the same information over and over for different countries. It saves time and reduces the chance that important details get lost or presented differently in different submissions. For you as a patient or consumer, it matters because it means the regulatory review process moves faster and more consistently, whether the medicine or device is being reviewed in one country or several.

Key Takeaways

  • A Common Technical Document is a standardized format that companies use to submit information about medicines and medical devices to government regulators.
  • The CTD is organized into five main sections: administrative information, summaries, quality data, nonclinical study reports, and clinical study reports.
  • Using a CTD speeds up the review process because regulators in different countries can read the same organized document instead of requiring separate submissions.
  • The CTD format is accepted by the FDA in the United States, the EMA in Europe, and regulatory agencies in Japan, Canada, Australia, and other countries.

The five main sections of a Common Technical Document

The CTD is divided into five numbered sections, each containing a specific type of information. This structure is the same no matter which country is reviewing it. The first section holds administrative details like the company name, the medicine or device name, and who is responsible for the submission. The second section contains summaries written for regulators who may not read every technical detail — these summaries highlight the key findings and safety information.

Sections three, four, and five contain the detailed technical data. Section three covers quality and manufacturing — how the medicine or device is made, what it contains, and how the company tests it to make sure each batch is safe and consistent. Section four holds nonclinical study reports, which are laboratory and animal studies done before any human testing. Section five contains clinical study reports, which are the results from studies done on actual patients or volunteers.

Each section builds on the others. A regulator can start with the summaries in section two to understand the big picture, then dive into the detailed reports in sections three, four, and five if they need more information to make a decision.

Who uses Common Technical Documents and why

Pharmaceutical companies, biotechnology firms, and medical device manufacturers use CTDs when they want to market a new product in multiple countries. A company developing a new cancer drug, for example, might want to sell it in the United States, the European Union, and Japan at the same time. Instead of creating three separate documents organized three different ways, they create one CTD and submit it to all three regulators.

Regulatory agencies use the CTD because it makes their job more consistent and efficient. When every submission follows the same format, reviewers can find the information they need faster. They can also compare data across different medicines more easily, which helps them spot patterns or safety concerns. The CTD also makes it easier for regulators in different countries to share information and coordinate their reviews.

How the Common Technical Document format started

Before the CTD existed, companies had to follow different rules in different countries. The FDA in the United States wanted information organized one way. European regulators wanted it organized another way. Japanese regulators had their own requirements. This meant companies had to hire teams of people to reformat and reorganize the same scientific data multiple times, which was expensive and time-consuming.

In the 1990s, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, known as ICH, brought together regulators and industry experts from the United States, Europe, and Japan to create a single standard format. The CTD was first published in 2003 and has been updated several times since. Today it is the standard format accepted by most major regulatory agencies around the world.

What information goes into each section of the CTD

The administrative section (Module 1) includes the cover letter, the application form, the company's curriculum vitae, and a list of all the documents included in the submission. This section is often customized for each country because different regulators have different forms and requirements.

The summaries section (Module 2) contains four key documents. The quality overall summary describes how the medicine or device is made and tested. The nonclinical overview and summaries explain what laboratory and animal studies showed. The clinical overview and summaries describe what happened in human studies. The clinical safety summary pulls together all the safety information from human studies into one place so regulators can see the full picture of risks.

The quality section (Module 3) includes detailed information about the drug substance (the active ingredient), the drug product (the final medicine), the container and closure system (how it is packaged), and the stability data (how long it stays safe and effective). This section also includes the analytical methods used to test the medicine and the results of those tests.

The nonclinical section (Module 4) contains all the laboratory studies and animal studies, organized by type — pharmacology studies, toxicology studies, and any other nonclinical work done. The clinical section (Module 5) contains all the human studies, including early-stage studies, late-stage studies, and any studies done after the medicine was already on the market.

How regulators use the Common Technical Document to make decisions

When a company submits a CTD to a regulatory agency, the agency assigns reviewers to each section. One team reviews the quality and manufacturing information. Another team reviews the nonclinical studies. A third team reviews the clinical studies. Because the CTD is organized the same way every time, each team knows exactly where to find the information they need.

The reviewers read through the summaries first to understand what the company is asking for and what the main findings are. If they have questions or need more detail, they can go directly to the section that contains the full report. They look for evidence that the medicine or device is safe and effective, that it is made consistently, and that the company has thought through potential risks. If the reviewers find problems or have questions, they send a list back to the company, and the company has a set amount of time to respond.

The entire review process typically takes several months to over a year, depending on how complex the medicine or device is and how quickly the company can answer questions. Using a standardized CTD format does not speed up the scientific review itself, but it does eliminate the time that would be spent reformatting and reorganizing information.

Frequently Asked Questions

Is the Common Technical Document the same in every country?

The five-section structure and the content of Modules 2 through 5 are the same everywhere. Module 1, the administrative section, is often customized because different countries have different forms and requirements. A company might submit the same CTD to the FDA and the EMA but include different cover letters and application forms for each one.

Can I look at a Common Technical Document for a medicine I take?

The full CTD is confidential and not released to the public because it contains proprietary information about how the medicine is made. However, regulatory agencies do release summaries of the safety and effectiveness data in documents called reviews or assessment reports, which you can often find on the agency's website.

What happens if a company does not use the Common Technical Document format?

Most major regulatory agencies now require the CTD format for new medicine and device submissions. If a company submits information in a different format, the agency will ask them to reformat it before the review can begin. This delays the submission and adds cost, so companies have strong incentive to use the CTD from the start.

Does using a Common Technical Document mean a medicine will be approved faster?

The CTD format makes the review process more organized and efficient, but it does not change how long the scientific review takes. The FDA and other agencies still need to carefully evaluate all the safety and effectiveness data, which can take many months. The CTD eliminates administrative delays but not scientific ones.

Who decides what goes into the Common Technical Document?

The International Council for Harmonisation, or ICH, maintains the CTD standard. ICH includes representatives from regulatory agencies in the United States, Europe, and Japan, as well as industry experts and consultants. When the standard needs to be updated, ICH publishes a new version that all member agencies agree to accept.